Deals Of The Week: Busy ROR Gamma T Space Offers Small Molecule Promise In Autoimmune Disorders
Executive Summary
Amgen’s July 31 deal with Japan’s Teijin marks at least the six partnerships around RORγt inhibitor compounds since 2009, with one more such deal likely this year. Plus news from a busy deal-making week, including tie-ups for AstraZeneca and Fibrogen, Actelion and Ceptaris, and Bristol and Samsung.
You may also be interested in...
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.
Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.